NON HODGKIN LYMPHOMA

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This early-phase trial tests whether giving siltuximab before epcoritamab can prevent cytokine release syndrome (CRS), a common and sometimes severe side effect. About 20 adults with non-Hodgkin lymphoma will receive siltuximab one hour before their first epcoritamab dose. Resear…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30…

This early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. About …

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This early-phase study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goa…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called epcoritamab given together with other anti-cancer medicines in adults with Non-Hodgkin lymphoma (NHL), a type of blood cancer. About 496 participants will receive different combinations depending on their lymphoma subtype and treatment…

This study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. …

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This study tests whether giving a single dose of a targeted radiation drug (Iomab-B) before standard CAR-T cell therapy can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 participants will receive the radiation followed by CAR-T ce…

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This study tests whether combining two oral drugs, pirtobrutinib and venetoclax, can control mantle cell lymphoma (MCL) in patients whose cancer has come back or hasn't responded to prior treatments. About 30 adults with confirmed MCL will take these pills to see how many achieve…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This study tests whether a prebiotic supplement called resistant starch can improve gut microbiome diversity in people with multiple myeloma or lymphoma after an autologous stem cell transplant. Thirty participants will take either the prebiotic or a placebo for about 10 days bef…

This study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…

This early-phase study tests an experimental oral drug called AUR108 in adults with relapsed advanced lymphomas. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 40 participants will take the pill, and researchers will m…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This study tests whether a drug called sargramostim can help restore white blood cells as quickly as the standard drug (G-CSF) after a half-matched stem cell transplant for blood cancers, while possibly lowering the risk of serious infections. About 38 adults with blood cancers l…

This early-phase study tests a new drug called KSV01 in 18 adults with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has not responded to standard treatments. The main goal is to check the safety of the injection and find the best dose. Partici…

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…

This study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…

This early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or…

This study tests a modified stem cell transplant regimen for lymphoma patients at high risk of the cancer spreading to the brain. About 45 adults who have already responded to initial treatment will receive high-dose chemotherapy with thiotepa, etoposide, cytarabine, and melphala…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if the drug shrinks tumors. Some participants with lymphoma will also receive the drug combined with rituximab. The st…

This early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 participants who completed an earlier pirtobrutinib study can join to keep receiving treatment or have follow-up visits. The main goal…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This phase 2 trial is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in 45 people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo shrinks tumors and how safe it …

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shr…

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This early-phase study tests whether a special cell therapy called T-allo10 can safely help rebuild the immune system in children and young adults (up to age 45) with blood cancers who have received a stem cell transplant. The treatment is given after the transplant to speed up r…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or stopped responding to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection a…

This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…

This early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…

This study tests whether low-intensity mechanical stimulation (LIMS) vibration therapy can help blood cancer patients who are about to receive a stem cell transplant or cell therapy. The vibration board sends gentle waves through the bones, which may stimulate bone growth, improv…

This study tests a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. Instead of giving everyone the drug plerixafor, doctors will start with G-CSF alone and only add plerixafor if needed. The goal is to s…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This early-stage study is testing a new drug called DCR-PDL1 in about 32 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and how the body processes it, not to cure the cancer. Participants will receive …

This phase 2 study tests a stem cell transplant procedure for people with Hodgkin or non-Hodgkin lymphoma, including those with HIV. Participants receive high-dose chemotherapy followed by an infusion of their own stem cells. The goal is to see if this radiation-free approach can…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete o…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This early-stage study is testing a new biologic drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check safety and find the right dose. Participants receive CC31…

This early-phase trial is testing whether a second infusion of the CAR T-cell therapy Axi-Cel (called Axi-Cel-2) is safe for people with high-risk large B-cell lymphoma whose cancer came back after standard CAR T treatment. About 20 adults will receive the second infusion and be …

This early-phase trial is testing a new type of immune cell therapy called TmCD19-IL18 CAR T cells in people with a blood cancer (non-Hodgkin lymphoma) that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them to be…

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…

This study looks at whether a wearable heart monitor and a symptom questionnaire can accurately detect autonomic dysfunction—a condition affecting heart rate and blood pressure control—in survivors of childhood leukemia and lymphoma. Researchers will compare these remote methods …

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study tests whether a tailored physical activity program can help lymphoma and breast cancer patients preserve their exercise ability, heart function, memory, and quality of life while undergoing cancer treatment. About 110 adults aged 18-85 with Hodgkin or non-Hodgkin lymph…

This study tests whether a Mediterranean diet and home-based exercise program can help lymphoma patients complete chemotherapy and reduce treatment-related side effects. Researchers will enroll 140 adults with untreated Hodgkin or non-Hodgkin lymphoma who need at least 6 cycles o…

This study tests a digital health program called AYA STEPS for adolescent and young adult cancer survivors. The program uses video sessions and online materials to teach skills for managing symptoms like pain, fatigue, and emotional distress, and to encourage follow-up care. Rese…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This observational study is recruiting 300 active-duty service members and military beneficiaries diagnosed with B-cell non-Hodgkin lymphoma. Researchers want to understand how exposure to toxins, genetic differences, and immune system problems are linked to this cancer. Particip…

This study examines how social and genetic factors influence long-term health in 2000 adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information to identify risks for disease recurrence, other illnesses, …

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study is testing whether daily voice recordings can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will use their smartphones to record their…

This observational study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. Researchers will track how often infections occur, how severe they are, and what factors raise infection risk. The goal is to better …

This study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …

This study looks at whether firefighters' exposure to hazardous chemicals leads to pre-cancerous changes in their blood. Researchers will collect blood samples from 300 firefighters aged 40-49 with at least 5 years on the job. The goal is to find early markers that might predict …

This study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…

This study interviews Spanish-speaking families of children with leukemia or lymphoma to learn about their experiences and challenges. Researchers want to understand what works well and what barriers exist in communication and access to care. The goal is to use these insights to …

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…

This study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma by studying families where more than one person has the disease. Researchers will collect DNA and blood samples from up to 500 participants, including patients and th…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a Bristol-Myers Squibb CAR-T cell therapy for blood cancers like lymphoma or myeloma. Researchers will test the new tumors for traces of the gene-modified cells used in the original tre…

This study looks at whether peer education and support can help more adolescents and young adults (ages 15-39) living with HIV get screened for cancer and stick with their cancer treatment. Researchers will work with 4,100 participants in Zambia to improve early diagnosis and tre…

This early-phase study is testing a new radioactive tracer called 64Cu-GRIP B, which is used in PET scans to detect immune cell activity. The goal is to see if this scan can predict which patients with relapsed non-Hodgkin lymphoma will have a lasting response to CAR-T cell thera…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study looks at how young people (ages 6-25) with Hodgkin or non-Hodgkin lymphoma process certain medications. Researchers will give tiny, non-therapeutic doses of two common drugs (omeprazole and dextromethorphan) and measure how they are broken down in the body. The goal is…